Biochemical measurements of endomyocardial biopsies

Unverferth, Donald V.; Fertel, Richard H.; Altschuld, Ruth A.; Magorien, Raymond D.; Lewis, Richard P.; Leier, Carl V.

doi:10.1002/ccd.1810070108

Cited by 17 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One might hope to circumvent the first problem by percutaneous biopsy through a catheter. However, this has been unsuccessful because the catabolism that results from failure to freeze the sample immediately in liquid nitrogen leads to significantly lower estimates of myocardial nucleoside triphosphate content (15). Performing biopsies at surgery obviates the problem of in vitro catabolism.…”

Section: Resultsmentioning

confidence: 99%

Derangements in myocardial purine and pyrimidine nucleotide metabolism in patients with coronary artery disease and left ventricular hypertrophy.

Swain¹,

Sabina²,

Peyton³

et al. 1982

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

Derangements in myocardial purine and pyrimidine nucleotide metabolism in patients with coronary artery disease and left ventricular hypertrophy ( Communicated by James B. Wyngaarden, October 5, 1981 ABSTRACT Studies in animal models of myocardial ischemia and left ventricular hypertrophy have demonstrated a number of derangements in purine and pyrimidine nucleotide content of myocardium that are postulated to play a role in the pathogenesis of muscle dysfunction in these disorders. The present study examined myocardium ofpatients with coronary artery disease, left ventricular hypertrophy, or neither of these two abnormalities, to determine whether derangements in purine and pyrimidine nucleotide metabolism occur in humans. In patients with coronary artery disease, endocardial content ofATP, GTP, UTP, CTP, and creatine phosphate was reduced and ranged between 60% and 86% of the amount found in the epicardium. In patients without coronary artery disease or ventricular hypertrophy, endocardial content of these nucleotides was equal to or greater than that of epicardium. Endocardial and epicardial content of inosine was increased in patients with coronary artery disease, and after vein bypass grafting inosine content fell to the levels observed in myocardium of patients with normal coronary arteries. In patients with left ventricular hypertrophy, endocardial content of ATP, GTP, UTP, CTP, and creatine phosphate was also reduced and ranged between 64% and 88% ofthe epicardial content. In contrast to results obtained in patients without left ventricular hypertrophy, epicardial content of GTP, UTP, and CTP was increased by 131%, 123%, and 132% in hypertrophied myocardium. Thus the changes noted in myocardial nucleotide content in patients are similar to those noted in animal models of occlusive coronary disease and ventricular hypertrophy. These results suggest that the pathophysiological abnormalities in nucleotide metabolism noted in animal models also occur in human myocardium.

show abstract

Section: Resultsmentioning

confidence: 99%

Derangements in myocardial purine and pyrimidine nucleotide metabolism in patients with coronary artery disease and left ventricular hypertrophy.

Swain¹,

Sabina²,

Peyton³

et al. 1982

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

show abstract

“…13 The biopsies were analyzed for magnesium, potassium, and protein content by the methods presented above for skeletal muscle and expressed as nanomoles of magnesium or potassium per milligram of protein.…”

Section: Procedures and Measurementsmentioning

confidence: 99%

Magnesium content of serum, circulating mononuclear cells, skeletal muscle, and myocardium in congestive heart failure.

et al. 1989

View full text Add to dashboard Cite

Deranged magnesium concentrations in serum and cardiovascular structures have been implicated in the pathophysiology of hypertension, ischemic heart disease, arrhythmias, and sudden death. This study was conducted to determine the status and interrelation of serum and tissue concentrations of magnesium in patients with congestive heart failure, a clinical setting purportedly predisposed to the development of depleted levels of this cation. Magnesium concentrations of serum, circulating mononuclear cells, skeletal muscle, and myocardium were measured in 23 patients with heart failure on standard therapy. Two patients were hypomagnesemic (<1.6 meq/l). Poor or no correlations were found between serum and tissue magnesium concentrations and among the magnesium concentrations of the three tissues studied. Strong direct correlations were, however, noted between magnesium and potassium concentrations of the tissues examined. The prevalence of hypomagnesemia in this typical ambulatory heart failure population is relatively low (9%o) and serum, circulating mononuclear cell, skeletal muscle, and myocardial magnesium concentrations correlate poorly with each other. Serum, circulating mononuclear cell, and skeletal muscle magnesium concentrations are thus of little predictive value in assessing the status of myocardial magnesium in humans with heart failure. (Circulation 1989;80:573-580) M agnesium, a biologically essential cation, has recently received considerable attention in clinical medicine, especially with regard to the role of its depletion in cardiovascular pathophysiology. Decreased magnesium stores have been implicated in the development and complications of atherosclerosis, myocardial infarction, hypertension, and dysrhythmias.1,2 Severe magnesium deficiency in animals has been shown to cause direct myocardial damage.3Patients with congestive heart failure would seem to be a group adversely susceptible to altered magnesium metabolism because these patients often have underlying myocardial damage and dysrhythmias and are receiving diuretics chronically. Diuretic therapy increases urinary magnesium losses and may cause depletion of total body and regional

show abstract

Endomyocardial biopsy: A review of the literature

Przybojewski

1985

Cathet. Cardiovasc. Diagn.

View full text Add to dashboard Cite

A review of the literature relating to endomyocardial biopsy (EMB) is presented. This is considered important at this time since EMB is being utilized with increasing frequency, particularly for the diagnosis of myocarditis. The development of the technique is briefly outlined. Emphasis is placed on the clinical application of EMB in the various primary cardiomyopathies (dilated, hypertrophic, restrictive, and obliterative), the infiltrative secondary cardiomyopathies (amyloidosis, sarcoidosis, hemochromatosis), myocarditis, as well as such conditions as adriamycin cardiotoxicity, cardiac transplant rejection, and Kawasaki disease. More controversial application of EMB in primary mitral valve prolapse (Barlow's syndrome), idiopathic ventricular arrhythmias, and the elucidation of the enigmatic finding of angina with angiographically normal coronary arteries is detailed. Experience with immunological and biochemical investigation of biopsy material, as well as with virus isolation and drug assays in the myocardium, is alluded to. Complications encountered with this procedure are also discussed, and its future role is contemplated.

show abstract

Biochemical measurements of endomyocardial biopsies

Cited by 17 publications

References 16 publications

Derangements in myocardial purine and pyrimidine nucleotide metabolism in patients with coronary artery disease and left ventricular hypertrophy.

Derangements in myocardial purine and pyrimidine nucleotide metabolism in patients with coronary artery disease and left ventricular hypertrophy.

Magnesium content of serum, circulating mononuclear cells, skeletal muscle, and myocardium in congestive heart failure.

Endomyocardial biopsy: A review of the literature

Contact Info

Product

Resources

About